This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

close

TAKING A SUPPORTIVE
CARE APPROACH BENEFITS
PATIENTS WITH
PULMONARY FIBROSIS1,2

PULMONARY REHABILITATION CAN SIGNIFICANTLY IMPROVE FUNCTIONAL
CAPACITY AND QUALITY OF LIFE IN PATIENTS WITH ILDs:1

Improvement in SGRQ quality of life score

6.1-point improvement in SGRQ quality of life score
(95%CI 3.7 to 8.6, P<0.0005)1
51% of patients achieved ≥5-point improvement in SGRQ1

Improvement in 6MWD immediately after rehabilitation

57.6 m improvement in 6MWD immediately after
rehabilitation (95%CI 40.2 to 75.1 m, P<0.0005)

MCID improvement in dyspnoea

65% of patients achieved MCID improvement in
dyspnoea1

MCID Improvement in depression score

52% of patients achieved MCID improvement in
depression score1

Numbers based on a prospective cohort study
SGRQ = St. George’s Respiratory Questionnaire, 6MWD = 6-minute walk distance, MCID = Minimum clinically important difference

The benefits of pulmonary rehabilitation last for
at least 6 months in most ILD patients1

Early supportive (palliative) care can help relieve symptoms and help maintain physical and emotional wellbeing in patients with progressive fibrosing ILD2 

HOLISTIC CARE SHOULD BE PROVIDED THROUGHOUT THE
DISEASE COURSE, TAILORED TO THE INDIVIDUAL NEEDS OF
PATIENTS WITH ILDs2,3

Diagram on the optimisation of quality of life care in patients with ILDs
Diagram on the optimisation of quality of life care in patients with ILDs

There is a broad range of approaches available to support patients with ILDs from pulmonary rehabilitation to mindfulness1-4

You can make a difference for your patients

References
  1. 1.

    Ryerson CJ, Cayou C, Topp F, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med. 2014;108(1):203-210.

  2. 2.

    Kreuter M, Bendstrup E, Russell A, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5(12):968-980.

  3. 3.

    Maher TM, Wuyts W. Management of Fibrosing Interstitial Lung Diseases. Adv Ther. 2019 May 22. doi: 10.1007/s12325-019-00992-9. [Epub ahead of print].

  4. 4.

    Sgalla G, Cerri S, Ferrari R, et al. Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. BMJ Open Respir Res. 2015;2(1):e000065.